Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children

  • Yang, Hyeon-Jong (Pediatric Allergy and Respiratory Center, Department of Pediatrics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine)
  • 투고 : 2018.12.20
  • 심사 : 2019.03.13
  • 발행 : 2019.06.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Although Mycoplasma pneumoniae pneumonia (MPP) has been generally susceptible to macrolides, the emergence of macrolide-resistant MPP (MRMP) has made its treatment challenging. MRMP rapidly spread after the 2000s, especially in East Asia. MRMP is more common in children and adolescents than in adults, which is likely related to the frequent use of macrolides for treating M. pneumoniae infections in children. MRMP is unlikely to be related to clinical, laboratory, or radiological severity, although it likely prolongs the persistence of symptoms and the length of hospital stay. Thereby, it causes an increased burden of the disease and poor quality of life for the patient as well as a societal socioeconomic burden. To date, the only alternative treatments for MRMP are secondary antimicrobials such as tetracyclines (TCs) or fluoroquinolones (FQs) or systemic corticosteroids; however, the former are contraindicated in children because of concerns about potential adverse events (i.e., tooth discoloration or tendinopathy). A few guidelines recommended TCs or FQs as the second-line drug of choice for treating MRMP. However, there have been no evidence-based guidelines. Furthermore, safety issues have not yet been resolved. Therefore, this article aimed to review the benefits and risks of therapeutic alternatives for treating MRMP in children and review the recommendations of international or regional guidelines and specific considerations for their practical application.

키워드

참고문헌

  1. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:e25-76. https://doi.org/10.1093/cid/cir531
  2. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17:697-728. https://doi.org/10.1128/CMR.17.4.697-728.2004
  3. Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2012;55:42-7. https://doi.org/10.3345/kjp.2012.55.2.42
  4. Becker A, Kannan TR, Taylor AB, Pakhomova ON, Zhang Y, Somarajan SR, et al. Structure of CARDS toxin, a unique ADP-ribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae. Proc Natl Acad Sci U S A 2015;112:5165-70. https://doi.org/10.1073/pnas.1420308112
  5. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev 2017;30:747-809. https://doi.org/10.1128/CMR.00114-16
  6. Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis 2013;19:1281-4. https://doi.org/10.3201/eid1908.121455
  7. Yoon IA, Hong KB, Lee HJ, Yun KW, Park JY, Choi YH, et al. Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia. BMC Infect Dis 2017;17:402. https://doi.org/10.1186/s12879-017-2500-z
  8. Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol 2016;7:693.
  9. Pereyre S, Goret J, Bebear C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 2016;7:974.
  10. Bebear C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011;6:423-31. https://doi.org/10.2217/fmb.11.18
  11. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55:1642-9. https://doi.org/10.1093/cid/cis784
  12. Tanaka T, Oishi T, Miyata I, Wakabayashi S, Kono M, Ono S, et al. Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008-2015. Emerg Infect Dis 2017;23:1703-6. https://doi.org/10.3201/eid2310.170106
  13. Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother 2009;15:380-3. https://doi.org/10.1007/s10156-009-0715-7
  14. Cardinale F, Chironna M, Chinellato I, Principi N, Esposito S. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol 2013;51:723-4. https://doi.org/10.1128/JCM.02840-12
  15. Wu PS, Chang LY, Lin HC, Chi H, Hsieh YC, Huang YC, et al. Epidemiology and clinical manifestations of children with macrolideresistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol 2013;48:904-11. https://doi.org/10.1002/ppul.22706
  16. Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012;17:354-62. https://doi.org/10.1111/j.1440-1843.2011.02102.x
  17. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006;50:709-12. https://doi.org/10.1128/AAC.50.2.709-712.2006
  18. Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2014;58:1034-8. https://doi.org/10.1128/AAC.01806-13
  19. The Committee of Japanese Society of Mycoplasmology. Guiding principles * for treating for treating Mycoplasma pneumoniae pneumonia [Internet]. Tokyo: Japanese Society of Mycoplasmology; 2014 [cited 2018 Dec 12]. Available from http://square.umin.ac.jp/jsm/Eng%20shisin.pdf.
  20. Lung DC, Lam DS, Chan E, Chan KC, Chiu SS, Ho PL, et al. Practice recommendations for management of community acquired pneumonia in children. HK J Paediatr 2016;21:178-93.
  21. Japan Pediatric Society. The Guidelines for the Management of Respiratory Infectious Diseases in Children. Tokyo: Japan Pediatric Society;2011 [cited 2018 Dec 5]. Available from https://www.jpeds.or.jp/uploads/files/saisin_130219_2.pdf.
  22. Smith CB, Friedewald WT, Chanock RM. Shedding of Mycoplasma pneumoniae after tetracycline and erythromycin therapy. N Engl J Med 1967;276:1172-5. https://doi.org/10.1056/NEJM196705252762103
  23. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013;57:4046-9. https://doi.org/10.1128/AAC.00663-13
  24. Morozumi M, Okada T, Tajima T, Ubukata K, Iwata S. Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolideresistant Mycoplasma pneumoniae. Int J Antimicrob Agents 2017;50:255-7. https://doi.org/10.1016/j.ijantimicag.2017.02.027
  25. Shwachman H, Fekete E, Kulczycki LL, Foley GE. The effect of longterm antibiotic therapy in patients with cystic fibrosis of the pancreas. Antibiot Annu 1958-1959;6:692-9.
  26. Swallow JN, De Haller J, Young WF. Side-effects to antibiotics in cystic fibrosis: dental changes in relation to antibiotic administration. Arch Dis Child 1967;42:311-8. https://doi.org/10.1136/adc.42.223.311
  27. Rebich T Jr, Kumar J, Brustman B. The St. Regis environmental health issue: assessment of dental defects. J Am Dent Assoc 1983;106:630-3. https://doi.org/10.14219/jada.archive.1983.0111
  28. Boast A, Curtis N, Gwee A. QUESTION 1: Teething issues: can doxycycline be safely used in young children? Arch Dis Child 2016;101:772-4. https://doi.org/10.1136/archdischild-2016-310863.140
  29. Todd SR, Dahlgren FS, Traeger MS, Beltran-Aguilar ED, Marianos DW, Hamilton C, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015;166:1246-51. https://doi.org/10.1016/j.jpeds.2015.02.015
  30. Anderson A, Bijlmer H, Fournier PE, Graves S, Hartzell J, Kersh GJ, et al. Diagnosis and management of Q fever--United States, 2013:recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 2013;62(RR-03):1-30.
  31. Gaillard T, Briolant S, Madamet M, Pradines B. The end of a dogma:the safety of doxycycline use in young children for malaria treatment. Malar J 2017;16:148. https://doi.org/10.1186/s12936-017-1797-9
  32. Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila) 2007;46:121-6. https://doi.org/10.1177/0009922806290026
  33. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005;27:1329-42. https://doi.org/10.1016/j.clinthera.2005.09.005
  34. Forti G, Benincori C. Doxycycline and the teeth. Lancet 1969;1:782. https://doi.org/10.1016/S0140-6736(69)91787-5
  35. Lambrou DB, Tahos BS, Lambrou KD. In vitro studies of the phenomenon of tetracycline incorporation into enamel. J Dent Res 1977;56:1527-32. https://doi.org/10.1177/00220345770560122201
  36. Poyhonen H, Nurmi M, Peltola V, Alaluusua S, Ruuskanen O, Lahdesmaki T. Dental staining after doxycycline use in children. J Antimicrob Chemother 2017;72:2887-90. https://doi.org/10.1093/jac/dkx245
  37. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002;36:1-12. https://doi.org/10.1067/mva.2002.125018
  38. Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, Drexler NA, Dumler JS, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. MMWR Recomm Rep 2016;65:1-44.
  39. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesia FA. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979;51:177-87. https://doi.org/10.1016/0041-008X(79)90020-6
  40. Pertuiset E, Lenoir G, Jehanne M, Douchain F, Guillot M, Menkes CJ. Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis. Rev Rhum Mal Osteoartic 1989;56:735-40.
  41. Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon injury and fluoroquinolone use: a systematic review. Drug Saf 2013;36:709-21. https://doi.org/10.1007/s40264-013-0089-8
  42. Tanne JH. FDA adds "black box" warning label to fluoroquinolone antibiotics. BMJ 2008;337:a816. https://doi.org/10.1136/bmj.a816
  43. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together [Internet]. Silver Spring (MD): U.S. Food & Drug Administration; 2016 [2018 Dec 12]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm.
  44. Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, et all. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007;26:879-91. https://doi.org/10.1097/INF.0b013e3180cbd382
  45. Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012;125:1228.e23-1228.e28. https://doi.org/10.1016/j.amjmed.2012.05.027
  46. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003;163:1801-7. https://doi.org/10.1001/archinte.163.15.1801
  47. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324:1306-7. https://doi.org/10.1136/bmj.324.7349.1306
  48. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 2011;96:874-80. https://doi.org/10.1136/adc.2010.208843
  49. Jackson MA, Schutze GE; Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics 2016;138(5). pii:e20162706.
  50. Matsuda K, Narita M, Sera N, Maeda E, Yoshitomi H, Ohya H, et al. Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis 2013;13:591. https://doi.org/10.1186/1471-2334-13-591
  51. Narita M, Tanaka H. Cytokines involved in the severe manifestations of pulmonary diseases caused by Mycoplasma pneumoniae. Pediatr Pulmonol 2007;42:397. https://doi.org/10.1002/ppul.20445
  52. Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2015;1:CD004875.
  53. Shan LS, Liu X, Kang XY, Wang F, Han XH, Shang YX. Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children. World J Pediatr 2017;13:321-7. https://doi.org/10.1007/s12519-017-0014-9
  54. Ayaslioglu E, Erkek E, Oba AA, Cebecioglu E. Doxycycline-induced staining of permanent adult dentition. Aust Dent J 2005;50:273-5. https://doi.org/10.1111/j.1834-7819.2005.tb00373.x
  55. Good ML, Hussey DL. Minocycline: stain devil? Br J Dermatol 2003;149:237-9. https://doi.org/10.1046/j.1365-2133.2003.05497.x
  56. Mozaffar T, Gordon PH. Minocycline-induced skin and dental pigmentations. Neurology 2006;67:2185. https://doi.org/10.1212/01.wnl.0000236899.91938.39
  57. Carris NW, Pardo J, Montero J, Shaeer KM. Minocycline as a substitute for doxycycline in targeted scenarios: a systematic review. Open Forum Infect Dis 2015;2:ofv178. https://doi.org/10.1093/ofid/ofv178
  58. Kashyap AS, Sharma HS. Discolouration of permanent teeth and enamel hypoplasia due to tetracycline. Postgrad Med J 1999;75:772.
  59. Nelson R, Parker SR. Doxycycline-induced staining of adult teeth: the first reported case. Arch Dermatol 2006;142:1081-2.
  60. Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996;23:516-20.
  61. Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS 2013;24:822-8. https://doi.org/10.1177/0956462413502008
  62. Gruson D, Pereyre S, Renaudin H, Charron A, Bebear C, Bebear CM. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother 2005;49:1190-3. https://doi.org/10.1128/AAC.49.3.1190-1193.2005
  63. Degrange S, Renaudin H, Charron A, Pereyre S, Bebear C, Bebear CM. Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother 2008;61:1390-2. https://doi.org/10.1093/jac/dkn118
  64. Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 1990;43:608-13. https://doi.org/10.4269/ajtmh.1990.43.608

피인용 문헌

  1. Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone : A case report vol.99, pp.28, 2020, https://doi.org/10.1097/md.0000000000021128
  2. Are alternative antibiotics needed for antibiotic-nonresponsive Mycoplasma pneumoniae pneumonia? vol.63, pp.2, 2019, https://doi.org/10.3345/kjp.2019.00332
  3. How can we treat childhood mycoplasma pneumonia in real practice? vol.8, pp.2, 2020, https://doi.org/10.4168/aard.2020.8.2.51
  4. Mycoplasma pneumoniae: Atypical Pathogen in Community Acquired Pneumonia vol.14, pp.4, 2019, https://doi.org/10.22207/jpam.14.4.04